AI is transforming biotechnology. Eli Lilly and Metis TechBio have announced a drug delivery research partnership with potential payments of up to $1.1 billion. Explore how AI-powered lipid nanoparticle technology could shape pharmaceutical innovation and create new opportunities in STEM.
Trending
- Daytona Raises $60 Million as AI Agents Drive Demand for Specialized Cloud Infrastructure
- Otter.ai Secures $320 Million in Growth Financing to Expand Enterprise AI
- From Pet Genetics Founder to Miami Investor: Anna Skaya’s Next Chapter in Entrepreneurship
- Eli Lilly Partners With Metis TechBio in AI-Driven Drug Delivery Deal Worth Up to $1.1 Billion
- Amazon Introduces TorchNeuron to Simplify AI Development on Its Trainium Chips
- Anthropic Proposes Public Benefit Fund as AI Companies Face Growing Questions About Social Impact
- Tenstorrent Raises $1.5 Billion as the Race for AI Computing Infrastructure Intensifies
- Why Major Websites Are Restricting AI Agents—and What It Means for the Future of Automation
